Coverage Launched on Canadian Specialty Pharma Co.

Research Report
  ()
This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report.

Telemedicine Co. Sees Record Revenues on Software, Services Sales

  ()
Reliq Health Technologies Inc. reports that software and services revenue continues to increase, leading to record cash intake for the quarter that ended Dec. 31, 2022.

Blockchain Co. Launches Digital Coupon Consumer App

  ()
Global Compliance Applications Corp. is launching a new app that will enable consumers to receive and share digital token coupons and store them in digital wallets.

New Skin Gene Therapy Gets PDUFA Date

Research Report
  ()
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report.

Novel Therapy Corp Captures More of US Licensing Market, First EU Segment

  ()
White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses – or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream.

AI-Infused Telehealth Platform Absorbs New Patients

  ()
Telemedicine company Reliq Health Technologies Inc., which uses artificial intelligence in its software's algorithms, has gained six new contracts and more than 3,000 new patients.

Biotech Co. Initiates Feasibility Study

  ()
This morning Awakn Life Sciences announced it had initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis ODT fast dissolve technology. Read more to learn what this means for the company, why this may be needed, and what experts are saying about Awakn. 

Addiction Therapy Company Secures Major UK Endorsement

  ()
Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region.

New Drug for Hearing Loss Approved for Clinical Trials

Research Report
  ()
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report.

Biopharma Gains Another Shot on Goal With IND Approval

Research Report
  ()
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.

Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus

  ()
Streetwise Reports sat down with Řyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus.

Med Tech Co. Well-Poised for Revenue Growth This Year

Research Report
  ()
New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report.

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment

  ()
This morning Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.

Biopharma Creating COVID Drug Gets US$8.2M From the DOD

Research Report
  ()
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.

Exploring Why The Economist Named this Biotech 'One To watch' in 2023

  ()
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.

Telehealth Co. Expects More Growth in 2023

  ()
Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program.

Expert Investing Ideas

"Positive Phase 2a data were achieved with AGN's ifenprodil."

–Dr. André Uddin, Research Capital Corporation


"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com


"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com


"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com


"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com


"It would be logical for AGN to develop ifenprodil for two indications."

–Dr. André Uddin, Research Capital Corporation


"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–Dr. André Uddin, Research Capital Corporation


Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Biopharma Co.'s Burn Tissue Removal Product Approved

Research Report
  ()
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.

Which Precious Metal Has Chen Excited for 2023?

  ()
It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year?

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio

Contributed Opinion
  ()
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.

Target Price Boosted 400% on Biopharma Co.

Research Report
  ()
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.

Biotech at Good Entry Point for Investors, Analyst Says

Research Report
  ()
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Tags:  Psychedelics